Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

I investigate special situations, pairs, and index rebalancing trades in Korea.

Korea / Special Sits, Pairs, Index Rebalancing

Equity Capital Markets

GeneOne Life Science Inc. / Equity Capital Markets

This rights offering of a small-cap stock, Gene One Life Science, is worth paying a bit of attention.It aims to raise a total of ₩870bil by offering 4.7M new shares (a 34.7% capital increase rate). Four bankers are working on this offering, and it is a standby offering backed by them. So, there is no cancellation risk. Allocation? All of the new shares will go to the stockholders.Today (May 18) is the 1st round pricing. It carries a higher discount rate (30%) than the usual 20%, which will likely lead to broader price discrepancies. Then, tomorrow (May 19) is the last day to be eligible for subscription rights, which will be trading on June 8~12. The final pricing is on June 22.<figure class="editor-figure mceNonEditable"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/134/052/original/13.png?1589754735" class="editor-image img-responsive" data-smartkarma-image-id="134052"></figure></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/132/628/original/22.png?1589154153" class="editor-image img-responsive" data-smartkarma-image-id="132628"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/132/629/original/23.png?1589154160" class="editor-image img-responsive" data-smartkarma-image-id="132629"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/134/021/original/12.png?1589747819" class="editor-image img-responsive" data-smartkarma-image-id="134021"></figure>

This rights offering of a small-cap stock, Gene One Life Science, is worth paying a bit of attention.It aims to raise a total of ₩870bil by offering 4.7M new shares (a 34.7% capital increase rate). Four bankers are working on this offering, and it is a standby offering backed by them. So, there is no cancellation risk. Allocation? All of the new shares will go to the stockholders.Today (May 18) is the 1st round pricing. It carries a higher discount rate (30%) than the usual 20%, which will likely lead to broader price discrepancies. Then, tomorrow (May 19) is the last day to be eligible for subscription rights, which will be trading on June 8~12. The final pricing is on June 22.

Gene One Life Rights Offer: How We Approach with Ex-Rights on May 19